Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690412 | 1.00 | POLB (0.46) | POLBAPEX1HPGDALDH1A1GPR27 | |
| SCHEMBL17071867 | 0.89 | POLB (0.43) | POLBAPEX1HPGDMAOBMAOA | |
| SCHEMBL15757221 | 0.87 | POLB (0.46) | POLBAPEX1HPGDMAOBMAOA | |
| SCHEMBL2630704 | 0.87 | POLB (0.46) | POLBAPEX1HPGDGPR27MAOB | |
| SCHEMBL6561685 | 0.86 | TSHR (0.46) | ALDH1A1MAOBMAOASMN1; SMN2TSHR | |
| SCHEMBL3621616 | 0.84 | POLB (0.56) | POLBAPEX1HPGDSMN1; SMN2TSHR | |
| SCHEMBL2075295 | 0.83 | KDM4E (0.42) | POLBAPEX1HPGDALDH1A1MAOB | |
| SCHEMBL4158847 | 0.83 | HTT (0.46) | POLBAPEX1HPGDALDH1A1MAOB | |
| SCHEMBL9618645 | 0.83 | HSP90AA1 (0.40) | POLBAPEX1HPGDALDH1A1MAOB | |
| SCHEMBL29495384 | 0.83 | HTT (0.46) | POLBAPEX1HPGDALDH1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113185533-B | Synthesis method of prifloxacin key intermediate | 浙江工业大学 | 2023-12-05 | — | — | CN | claimed |
| EP-4081215-B1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4605388-A1 | <SUP2/>? <SUB2/>?3?2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CXCR1 | Astrazeneca AB (SE) | 2025-08-27 | — | — | EP | disclosed |
| CN-120077035-A | As CX32,4, 6-Trisubstituted 1,3, 5-triazines as modulators of CR1 | 阿斯利康(瑞典)有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2024083933-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX 3CR1 | ASTRAZENECA AB (SE) | 2024-04-25 | — | — | WO | disclosed |
| US-20240018108-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2024-01-18 | — | — | US | disclosed |
| CN-113185533-B | Synthesis method of prifloxacin key intermediate | 浙江工业大学 | 2023-12-05 | — | — | CN | disclosed |
| CN-113185533-B | Synthesis method of prifloxacin key intermediate | 浙江工业大学 | 2023-12-05 | — | — | CN | disclosed |
| CN-115361948-A | Methods and compositions for inhibiting dihydroorotate dehydrogenase | 俄亥俄州国家创新基金会 | 2022-11-18 | — | — | CN | disclosed |
| EP-4081215-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | Ohio State Innovation Foundation (US) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018108-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | DHODH, DLD, FAH | POLB 1706/4885APEX1 1454/4885HPGD 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.